Tonix Pharmaceuticals (NASDAQ:TNXP) Trading Down 3.5% – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) shares traded down 3.5% during trading on Friday . The company traded as low as $0.29 and last traded at $0.30. 25,356,621 shares traded hands during trading, a decline of 38% from the average session volume of 41,203,656 shares. The stock had previously closed at $0.31.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Tonix Pharmaceuticals in a research report on Wednesday. They issued a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Down 5.3 %

The stock’s 50 day simple moving average is $0.24 and its two-hundred day simple moving average is $0.37. The stock has a market capitalization of $55.60 million, a PE ratio of -0.01 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million during the quarter, compared to the consensus estimate of $2.63 million. On average, sell-side analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.